The pathologic diagnosis of mantle cell lymphoma.
Journal
Histology and histopathology
ISSN: 1699-5848
Titre abrégé: Histol Histopathol
Pays: Spain
ID NLM: 8609357
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
12
6
2021
medline:
29
3
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma usually characterized by t(11;14) (q13;q32), or CCND1 translocation and Cyclin D1 over expression. A very small subset of MCL may lack the t(11;14) (q13;q32) translocation and Cyclin D1 over expression, but show alternative translocations involving CCND2 and CCND3, and over expression of SOX11. In general, MCL has been considered a very aggressive and incurable lymphoma and patients with MCL usually have a poor prognosis. However, indolent variants, including in situ mantle cell neoplasm and the recently recognized leukemic non-nodal MCL do exist. In recent years, genome-wide molecular genetic studies have revealed a characteristic MCL genetic profile. This review will focus on the pathologic diagnosis of MCL using the traditional morphological and immunophenotypic strategies combined with cytogenetic characteristics and recently identified molecular profile. Morphological subtypes, immunophenotypic variants, recently recognized indolent variants, as well as MCL risk stratification will also be discussed.
Identifiants
pubmed: 34114641
pii: HH-18-351
doi: 10.14670/HH-18-351
doi:
Substances chimiques
CCND1 protein, human
0
CCND2 protein, human
0
CCND3 protein, human
0
Cyclin D2
0
Cyclin D3
0
Cyclin D1
136601-57-5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1051Références
Adam P., Schiefer A-I., Prill S., Henopp T., Quintanilla-Martinez L., Bösmüller H-C., Chott A. and Fend F. (2012). Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. Mod. Pathol. 25, 1629-1636.
pubmed: 22790016
Akhter A., Mahe E., Street L., Pournazari P., Perizzolo M., Shabani-Rad M-T., Stewart D.A. and Mansoor A. (2015). CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. J. Clin. Pathol. 68, 844-848.
pubmed: 26124315
Aukema S.M., Hoster E., Rosenwald A., Canoni D., Delfau-Larue M-H., Rymkiewicz G., Thorns C., Hartmann S., Kluin-Nelemans H., Hermine O., Dreyling M. and Klapper W. (2018). Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki67 in trials of the European MCL Network. Blood 131, 417-420.
pubmed: 29196411
Balsas P., Palomero J., Eguileor A., Rodriguez M.L., Vegliante M.C., Planas-Rigol E., Sureda-Gomez M., Cid M.C., Campo E. and Amador V. (2017). SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood 130, 501-513.
pubmed: 28533307
Baraban E., Sadigh S., Rosenbaum J., Van Arnam J., Bogusz A.M., Mehr C. and Bagg A. (2019). Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease. Br. J. Haematol. 186, 837-844.
pubmed: 31172509
Bea S. and Amador V. (2017). Role of SOX11 and genetic events cooperating with Cyclin D1 in mantle cell lymphoma. Curr. Oncol. Rep. 19, 43.
pubmed: 28466437
Bea S., Ribas M., Hernandez J.M., Bosch F., Pinyol M., Hernandez L., Garcia J.L., Flores T., Gonzalez M., Lopez-Guillermo A., Piris M.A., Cardesa A., Montserrat E., Miro R. and Campo E. (1999). Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93, 4365-4374.
pubmed: 10361135
Bea S., Salaverria I., Armengol L., Pinyol M., Fernandez V., Hartmann E.M., Jares P., Amador V., Hernandez L., Navarro A., Ott G., Rosenwald A., Estivill X. and Campo E.. (2009). Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution wholegenome profiling. Blood 113, 3059-3069.
pmcid: PMC2662646
pubmed: 18984860
Beekman R., Amador V. and Campo E. (2018). SOX11, a key oncogenic factor in mantle cell lymphoma. Curr. Opin. Hematol. 25, 299-306.
pubmed: 29738333
Camacho F.I., Garcia J.F., Cigudosa J.C., Mollejo M., Algara P., RuizBallesteros E., Gonzalvo P., Martin P., Perez-Seoane C., SanchezGarcia J. and Piris M.A. (2004). Aberrant Bcl6 protein expression in mantle cell lymphoma. Am. J. Surg. Pathol. 28, 1051-1056.
pubmed: 15252312
Carvajal-Cuenca A., Sua L.F., Silva N.M., Pittaluga S., Royo C., Song J.Y., Sargent R.L., Espinet B., Climent F., Jacobs S.A., Delabie J., Naresh K.N., Bagg A., Brousset P., Warnke R.A., Serrano S., Harris N.L., Swerdlow S.H., Jaffe E.S. and Campo E. (2012). In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97, 270-278.
pmcid: PMC3269489
pubmed: 22058203
Cheah C.Y. and Seymour J.F. (2013). Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. Leuk. Lymphoma 54, 1859-1861.
pubmed: 23432685
Cheah C.Y., George A., Gine E., Chiappella A., Kluin-Nelemans H.C., Jurczak W., Krawczyk K., Mocikova H., Klener P., Salek D., Walewski J., Szymczyk M., Smolej L., Auer R.L., Ritchie D.S., Arcaini L., Williams M.E., Dreyling M., Seymour J.F. and Network European Mantle Cell Lymphoma. (2013). Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann. Oncol. 24, 2119-2123.
pubmed: 23616279
Chen B.J., Ruminy P., Roth C.G., Bisig B., Mankel B., Steinhilber J., Bohers E., Jardin F., Fend F., Swerdlow S.H., Copie-Bergman C., de Leval L. and Quintanilla-Martinez L. (2019). Cyclin D1-positive mediastinal large B-cell lymphoma with copy number gains of CCND1 gene: A study of 3 cases with nonmediastinal disease. Am. J. Surg. Pathol. 43, 110-120.
pubmed: 30211726
Chen Y.H., Gao J., Fan G. and Peterson L.C. (2010). Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod. Pathol. 23, 105-112.
pubmed: 19801969
Clot G., Jares P., Gine E., Navarro A., Royo C., Pinyol M., Martin-Garcia D., Demajo S., Espinet B., Salar A., Ferrer A., Muntanola A., Aymerich M., Rauert-Wunderlich H., Jaffe E.S., Connors J.M., Gascoyne R.D., Delabie J., Lopez-Guillermo A., Ott G., Wright G.W., Staudt L.M., Rosenwald A., Scott D.W., Rimsza L.M., Bea S. and Campo E. (2018). A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 132, 413-422.
pmcid: PMC6071558
pubmed: 29769262
Cohen P.L., Kurtin P.J., Donovan K.A. and Hanson C.A. (1998). Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br. J. Haematol. 101, 302-310.
pubmed: 9609526
Cuneo A., Bigoni R., Rigolin G.M., Roberti M.G., Bardi A., Piva N., Milani R., Bullrich F., Veronese M.L., Croce C., Birg F., Dohner H., Hagemeijer A. and G. Castoldi G. (1999). Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood 93, 1372-1380.
pubmed: 9949181
de Boer C.J., Kluin-Nelemans J.C., Dreef E., Kester M.G., Kluin P.M., Schuuring E. and van Krieken J.H. (1996). Involvement of the CCND1 gene in hairy cell leukemia. Ann. Oncol. 7, 251-256.
pubmed: 8740788
Determann O., Hoster E., Ott G., Wolfram Bernd H., Loddenkemper C., Leo Hansmann M., Barth T.E., Unterhalt M., Hiddemann W., Dreyling M., Klapper W. and Network European Mantle Cell Lymphoma, and Group the German Low Grade Lymphoma Study. (2008). Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111, 2385- 2387.
pubmed: 18077791
Dictor M., Ek S., Sundberg M., Warenholt J., Gyorgy C., Sernbo S., Gustavsson E., Abu-Alsoud W., Wadstrom T. and Borrebaeck C. (2009). Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 94, 1563-1568.
pmcid: PMC2770967
pubmed: 19880779
Dreyling M., Klapper W. and Rule S. (2018). Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!. Blood 132, 2722-2729.
pubmed: 30385481
Dreyling M., Kluin-Nelemans H.C., Bea S., Hartmann E., Salaverria I., Hutter G., Perez-Galan P., Roue G., Pott C., Le Gouill S., Cortelazzo S., Rule S., Hess G., Zaja F., Vitolo U., Szymczyk M., Walewski J., Ribrag V., Unterhalt M., Hermine O., Hoster E. and Network European Mantle Cell Lymphoma. (2011). Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk. Lymphoma 52, 2226-2236.
pubmed: 21851218
Ek S., Dictorc M., Jerkeman M., Jirstrom K. and Borrebaeck C.A. (2008). Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 111, 800- 805.
pubmed: 17934069
Eskelund C.W., Dahl C., Hansen J.W., Westman M., Kolstad A., Pedersen L.B., Montano-Almendras C.P., Husby S., Freiburghaus C., Ek S., Pedersen A., Niemann C., Raty R., Brown P., Geisler C.H., Andersen M.K., Guldberg P., Jerkeman M. and Gronbaek K. (2017). TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130, 1903-1910.
pubmed: 28819011
Fernandez V., Salamero O., Espinet B., Sole F., Royo C., Navarro A., Camacho F., Bea S., Hartmann E., Amador V., Hernandez L., Agostinelli C., Sargent R.L., Rozman M., Aymerich M., Colomer D., Villamor N., Swerdlow S.H., Pileri S.A., Bosch F., Piris M.A., Montserrat E., Ott G., Rosenwald A., Lopez-Guillermo A., Jares P., Serrano S. and Campo E. (2010). Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70, 1408-1418.
pubmed: 20124476
Ferrer A., Salaverria I., Bosch F., Villamor N., Rozman M., Bea S., Gine E., Lopez-Guillermo A., Campo E. and Montserrat E. (2007). Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 109, 2473-2480.
pubmed: 17477385
Fu K., Weisenburger D.D, Greiner T.C., Dave S., Wright G., Rosenwald A., Chiorazzi M., Iqbal J., Gesk S., Siebert R., De Jong D., Jaffe E.S., Wilson W.H., Delabie J., Ott G., Dave B.J., Sanger W.G., Smith L.M., Rimsza L., Braziel R.M., Muller-Hermelink H.K., Campo E., Gascoyne R.D., Staudt L.M., Chan W.C. and Project Lymphoma/Leukemia Molecular Profiling. (2005). Cyclin D1- negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106, 4315-4321.
pmcid: PMC1895253
pubmed: 16123218
Fuster C., Martin-Garcia D., Balague O., Navarro A., Nadeu F., Costa D., Prieto M., Salaverria I., Espinet B., Rivas-Delgado A., Terol M.J., Gine E., Forcada P., Ashton-Key M., Puente X.S., Swerdlow S.H., Bea S. and Campo E. (2020). Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)- negative mantle cell lymphoma. Haematologica 105, e408-e411.
pmcid: PMC7395285
pubmed: 31753927
Garces S., Yin C.C., Patel K.P., Khoury J.D., Manning Jr. J.T., Li S., Xu J., Pina-Oviedo S., Johnson M.R., Gonzalez S., Molgo M., RuizCordero R. and Medeiros L.J. (2019). Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod. Pathol. 32, 16-26.
pubmed: 30323237
Greenwell I.B., Staton A.D., Lee M.J., Switchenko J.M., Saxe D.F., Maly J.J., Blum K.A., Grover N.S., Mathews S.P., Gordon M.J., Danilov A.V., Epperla N., Fenske T.S., Hamadani M., Park S.I., Flowers C.R. and Cohen J.B. (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124, 2306-2315.
pmcid: PMC5992038
pubmed: 29579328
Hartmann E., Fernandez V., Moreno V., Valls J., Hernandez L., F. Bosch F., Abrisqueta P., Klapper W., Dreyling M., Hoster E., MullerHermelink H.K., Ott G., Rosenwald A. and Campo E. (2008). Fivegene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J. Clin. Oncol. 26, 4966- 4972.
pubmed: 18606985
Hernandez L., Fest T., Cazorla M., Teruya-Feldstein J., Bosch F., Peinado M.A., Piris M.A., Montserrat E., Cardesa A., Jaffe E.S., Campo E. and Raffeld M. (1996). p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87, 3351-3359.
pubmed: 8605352
Hernandez L., Hernandez S., Bea S., Pinyol M., Ferrer A., Bosch F., Nadal A., Fernandez P.L., Palacin A., Montserrat E. and Campo E. (1999). c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 13, 2087-2093.
pubmed: 10602433
Hill H.A., Qi X., Jain P., Nomie K., Wang Y., Zhou S. and Wang M.L. (2020). Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 4, 2927-2938.
pmcid: PMC7362354
pubmed: 32598477
Holte H., Beiske K., Boyle M., Troen G., Blaker Y.N., Myklebust J., Kvaloy S., Rosenwald A., Lingjaerde O.C., Rimsza L.M., Smeland E.B., Scott D.W. and Kolstad A. (2018). The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Br. J. Haematol. 183, 225-234.
pmcid: PMC6530911
pubmed: 30080252
Hoster E., Dreyling M., Klapper W., Gisselbrecht C., van Hoof A., KluinNelemans H.C., Pfreundschuh M., Reiser M., Metzner B., Einsele H., Peter N., Jung W., Wormann B., Ludwig W.D., Duhrsen U., Eimermacher H., Wandt H., Hasford J., Hiddemann W., Unterhalt M. and Group German Low Grade Lymphoma Study, and Network European Mantle Cell Lymphoma. (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558-565.
pubmed: 17962512
Hoster E., Klapper W., Hermine O., Kluin-Nelemans H.C., Walewski J., van Hoof A., Trneny M., Geisler C.H., Di Raimondo F., Szymczyk M., Stilgenbauer S., Thieblemont C., Hallek M., Forstpointner R., Pott C., Ribrag V., Doorduijn J., Hiddemann W., Dreyling M.H. and Unterhalt M. (2014). Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J. Clin. Oncol. 32, 1338-1346.
pubmed: 24687837
Hoster E., Rosenwald A., Berger F., Bernd H.W., Hartmann S., Loddenkemper C., Barth T.F., Brousse N., Pileri S., Rymkiewicz G., Kodet R., Stilgenbauer S., Forstpointner R., Thieblemont C., Hallek M., Coiffier B., Vehling-Kaiser U., Bouabdallah R., Kanz L., Pfreundschuh M., Schmidt C., Ribrag V., Hiddemann W., Unterhalt M., Kluin-Nelemans J.C., Hermine O., Dreyling M.H. and Klapper W. (2016). Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the European Mantle Cell Lymphoma Network. J. Clin. Oncol. 34, 1386- 1394.
pubmed: 26926679
Hsi E.D. and Martin P. (2014). Indolent mantle cell lymphoma. Leuk. Lymphoma 55, 761-767.
pubmed: 23927395
Hsiao S.C., Cortada I.R., Colomo L., Ye H., Liu H., Kuo S.Y., Lin S.H., Chang S.T., Kuo T.U., Campo E. and Chuang S.S. (2012). SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology 61, 685-693.
pubmed: 22642745
Hu Z., Sun Y., Schlette E.J., Tang G., Li S., Xu J., Yin C.C., Young K.H., Patel K.P., Miranda R.N., Goswami M., Wang M., Jorgensen J.L., Medeiros L.J. and Wang S.A. (2018). CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod. Pathol. 31, 327-336.
pubmed: 28984300
Iaccarino I., Afify L., Aukema S.M., Reddemann K., Schutt P., Flur M. and Klapper W. (2018). t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform. Haematologica 103, e432-e435.
pmcid: PMC6119140
pubmed: 29773591
Jares P., Campo E., Pinyol M., Bosch F., Miquel R., Fernandez P.L., Sanchez-Beato M., Soler F., Perez-Losada A., Nayach I., Mallofre C., Piris M.A., Montserrat E. and Cardesa A. (1996). Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am. J. Pathol. 148, 1591-600.
pmcid: PMC1861570
pubmed: 8623927
Jares P., Colomer D. and Campo E. (2012). Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416-3423.
pmcid: PMC3461905
pubmed: 23023712
Katzenberger T., Petzoldt C., Holler S., Mader U., Kalla J., Adam P., Ott M.M., Muller-Hermelink H.K., Rosenwald A. and Ott G. (2006). The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107, 3407.
pubmed: 16597597
Kelemen K., Peterson L.C., Helenowski I., Goolsby C.L., Jovanovic B., Miyata S., Aranha O., Rosen S.T., Winter J.N., Nelson B.P., Gordon L.I. and Evens A.M. (2008). CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am. J. Clin. Pathol. 130, 166-177.
pubmed: 18628084
Klapper W., Hoster E., Determann O., Oschlies I., van der Laak J., Berger F., Bernd H.W., Cabecadas J., Campo E., Cogliatti S., Hansmann M.L., Kluin P.M., Kodet R., Krivolapov Y.A., Loddenkemper C., Stein H., Moller P., Barth T.E., Muller-Hermelink K., Rosenwald A., Ott G., Pileri S., Ralfkiaer E., Rymkiewicz G., van Krieken J.H., Wacker H.H., Unterhalt M., Hiddemann W., Dreyling M. and European MCL Networl. (2009). Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J. Hematop. 2, 103- 111.
pmcid: PMC2725281
pubmed: 19669190
Lecluse Y., Lebailly P., Roulland S., Gac A.C., Nadel B. and Gauduchon P. (2009). t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 23, 1190-1193.
pubmed: 19242498
Li J.Y., Gaillard F., Moreau A., Harousseau J.L., Laboisse C., Milpied N., Bataille R. and Avet-Loiseau H. (1999). Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am. J. Pathol. 154, 1449-1452.
pmcid: PMC1866594
pubmed: 10329598
Majlis A., Pugh W.C., Rodriguez M.A., Benedict W.F. and Cabanillas F. (1997). Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J. Clin. Oncol. 15, 1664-1671.
pubmed: 9193367
Martin-Garcia D., Navarro A., Valdes-Mas R., Clot G., Gutierrez-Abril J., Prieto M., Ribera-Cortada I., Woroniecka R., Rymkiewicz G., Bens S., de Leval L., Rosenwald A., Ferry J.A., His E.D., Fu K., Delabie J., Weisenburger D., de Jong D., Climent F., O'Connor S.J., Swerdlow S.H., Torrents D., Beltran S., Espinet B., Gonzalez-Farre B., Veloza L., Costa D., Matutes E., Siebert R., Ott G., QuintanillaMartinez L., Jaffe E.S., Lopez-Otin C., Salaverria I., Puente X.S., Campo E. and Bea S. (2019). CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma. Blood 133, 940-951.
pmcid: PMC6396173
pubmed: 30538135
Miao Y., Lin P., Saksena A., Xu J., Wang M., Romaguera J., Yin C.C., Medeiros L.J. and Li S. (2019). CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. Am. J. Surg. Pathol. 43, 1052-1060.
pubmed: 31045891
Mozos A., Royo C., Hartmann E., De Jong D., Baro C., Valera A., Fu K., Weisenburger D.D., Delabie J., Chuang S.S., Jaffe E.S., RuizMarcellan C., Dave S., Rimsza L., Braziel R., Gascoyne R.D., Sole F., Lopez-Guillermo A., Colomer D., Staudt L.M., Rosenwald A., Ott G., Jares P. and Campo E. (2009). SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1- negative subtype. Haematologica 94, 1555-1562.
pmcid: PMC2770966
pubmed: 19880778
Nadeu F., Martin-Garcia D., Clot G., Diaz-Navarro A., Duran-Ferrer M., Navarro A., Vilarrasa-Blasi R., Kulis M., Royo R., Gutierrez-Abril J., Valdes-Mas R., Lopez C., Chapaprieta V., Puiggros M., Castellano G., Costa D., Aymerich M., Jares P., Espinet B., Muntanola A., Ribera-Cortada I., Siebert R., Colomer D., Torrents D., Gine E., Lopez-Guillermo A., Kuppers R., Martin-Subero J.I., Puente X.S., Bea S. and Campo E. (2020). Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136, 1419-1432.
pmcid: PMC7498364
pubmed: 32584970
Navarro A., Clot G., Royo C., Jares P., Hadzidimitriou A., Agathangelidis A., Bikos V., Darzentas N., Papadaki T., Salaverria I., Pinyol M., Puig X., Palomero J., Vegliante M.C., Amador V., Martinez-Trillos A., Stefancikova L., Wiestner A., Wilson W., Pott C., Calasanz M.J., Trim N., Erber W., Sander B., Ott G., Rosenwald A., Colomer D., Gine E., Siebert R., Lopez-Guillermo A., Stamatopoulos K., Bea S. and Campo E. (2012). Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 72, 5307-5316.
pmcid: PMC3763938
pubmed: 22915760
Nordstrom L., Sernbo S., Eden P., Gronbaek K., Kolstad A., Raty R., Karjalainen M.L., Geisler C., Ralfkiaer E., Sundstrom C., Laurell A., Delabie J., Ehinger M., Jerkeman M. and Ek S. (2014). SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br. J. Haematol. 166, 98-108.
pmcid: PMC4282019
pubmed: 24684350
Nygren L., Baumgartner Wennerholm S., Klimkowska M., Christensson B., Kimby E. and Sander B. (2012). Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119, 4215- 4223.
pubmed: 22431568
Oberley M.J., Rajguru S.A., Zhang C., Kim K., Shaw G.R., Grindle K.M., Kahl B.S., Kanugh C., Laffin J. and Yang D.T. (2013). Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology 63, 499-508.
pmcid: PMC3871984
pubmed: 23926923
Orchard J., Garand R., Davis Z., Babbage G., Sahota S., Matutes E., Catovsky D., Thomas P.W., Avet-Loiseau H. and Oscier D. (2003). A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101, 4975-4981.
pubmed: 12609845
Ott M.M., Ott G., Kuse R., Porowski P., Gunzer U., Feller A.C. and Muller-Hermelink H.K. (1994). The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology 24, 329-334.
pubmed: 8045522
Palomero J., Vegliante M.C., Rodriguez M.L., Eguileor A., Castellano G., Planas-Rigol E., Jares P., Ribera-Cortada I., Cid M.C., Campo E. and Amador V. (2014). SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 124, 2235-2247.
pubmed: 25092176
Palomero J., Vegliante M.C., Eguileor A., Rodriguez M.L., Balsas P., Martinez D., Campo E. and Amador V. (2016). SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. Leukemia 30, 1596-1599.
pubmed: 26710884
Peterson J.F., Baughn L.B., Ketterling R.P., Pitel B.A., Smoley S.A., Vasmatzis G., Smadbeck J.B., Greipp P.T., Mangaonkar A.A., Thompson C.A., Parikh S.A., Chen D. and Viswanatha D.S. (2019). Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv. 3, 1298-1302.
pmcid: PMC6482352
pubmed: 31015206
Piris M.A., Mollejo M., Campo E., Menarguez J., Flores T. and Isaacson P.G. (1998). A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. Histopathology 33, 230-239.
pubmed: 9777389
Pittaluga S., Verhoef G., Criel A., Maes A., Nuyts J., Boogaerts M. and De Wolf Peeters C. (1996). Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk. Lymphoma 21, 115-125.
pubmed: 8907278
Pizzi M., Agostinelli C., Righi S., Gazzola A., Mannu C., Galuppini F., Fassan M., Visentin A., Piazza F., Semenzato G.C., Rugge M. and Sabattini E. (2017). Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology 71, 769-777.
pubmed: 28628241
Polonis K., Schultz M.J., Olteanu H., Smadbeck J.B., Johnson S.H., Vasmatzis G., Xu X., Greipp P.T., Ketterling R.P., Hoppman N.L., Baughn L.B. and Peterson J.F. (2020). Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Ann. Diagn. Pathol. 46, 151533.
pubmed: 32408254
Puente X.S., Jares P. and Campo E. (2018). Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 131, 2283-2296.
pubmed: 29666114
Quintanilla-Martinez L., Davies-Hill T., Fend F., Calzada-Wack J., Sorbara L., Campo E., Jaffe E.S. and Raffeld M. (2003). Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101, 3181-3187.
pubmed: 12515730
Ramsower C.A., Maguire A., Robetorye R.S., Feldman A.L., Syrbu S.I., Rosenthal A.C. and Rimsza L.M. (2020). Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. J. Hematop. 13, 231-238.
pmcid: PMC7661397
pubmed: 33193905
Rauert-Wunderlich H., Mottok A., Scott D.W., Rimsza L.M., Ott G., Klapper W., Unterhalt M., Kluin-Nelemans H.C., Hermine O., Hartmann S., Thorns C., Rymkiewicz G., Holte H., Dreyling M., Hoster E. and Rosenwald A. (2019). Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. Br. J. Haematol. 184, 616-624.
pmcid: PMC6361690
pubmed: 30095158
Ribera-Cortada I., Martinez D., Amador V., Royo C., Navarro A., Bea S., Gine E., de Leval L., Serrano S., Wotherspoon A., Colomer D., Martinez A. and Campo E. (2015). Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11- negative subtype. Mod. Pathol. 28, 1435-1447
pubmed: 26360498
Romaguera J.E., Medeiros L.J., Hagemeister F.B., Fayad L.E., Rodriguez M.A., Pro B., Younes A., McLaughlin P., Goy A., Sarris A.H., Dang N.H., Samaniego F., Brown H.M., Gagneja H.K. and Cabanillas F. (2003). Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97, 586-591.
pubmed: 12548600
Royo C., Salaverria I., Hartmann E.M., Rosenwald A., Campo E. and Bea S. (2011). The complex landscape of genetic alterations in mantle cell lymphoma. Semin. Cancer Biol. 21, 322-334.
pubmed: 21945515
Royo C., Navarro A., Clot G., Salaverria I., Gine E., Jares P., Colomer D., Wiestner A., Wilson W.H., Vegliante M.C., Fernandez V., Hartmann E.M., Trim N., Erber W.N., Swerdlow S.H., Klapper W., Dyer M.J., Vargas-Pabon M., Ott G., Rosenwald A., Siebert R., Lopez-Guillermo A., Campo E. and Bea S. (2012). Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26, 1895-1898.
pmcid: PMC4172376
pubmed: 22425896
Saksena A., Yin C.C., Xu J., Li J., Zhou J., Wang S.A., Lin P., Tang G., Wang L., Wang M., Miranda R.N., Medeiros L.J. and Li S. (2019). CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum. Pathol. 89, 71-80.
pubmed: 31054894
Salaverria I., Zettl A., Bea S., Moreno V., Valls J., Hartmann E., Ott G., Wright G., Lopez-Guillermo A., Chan W.C., Weisenburger D.D., Gascoyne R.D., Grogan T.M., Delabie J., Jaffe E.S., Montserrat E., Muller-Hermelink H.K., Staudt L.M., Rosenwald A. and Campo E. (2007). Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J. Clin. Oncol. 25, 1216- 22.
pmcid: PMC2366164
pubmed: 17296973
Salaverria I., Royo C., Carvajal-Cuenca A., Clot G., Navarro A., Valera A., Song J.Y., Woroniecka R., Rymkiewicz G., Klapper W., Hartmann E.M., Sujobert P., Wlodarska I., Ferry J.A., Gaulard P., Ott G., Rosenwald A., Lopez-Guillermo A., Quintanilla-Martinez L., Harris N.L., Jaffe E.S., Siebert R., Campo E. and Bea S. (2013). CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121, 1394-402.
pmcid: PMC3578954
pubmed: 23255553
Sander B., Quintanilla-Martinez L., Ott G., Xerri L., Kuzu I., Chan J.K., Swerdlow S.H. and Campo E. (2016). Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch. 468, 245-257.
pubmed: 26298543
Schlette E., Lai R., Onciu M., Doherty D., Bueso-Ramos C. and Medeiros L.J. (2001). Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod. Pathol. 14, 1133- 1140.
pubmed: 11706075
Schlette E., Fu K. and Medeiros L.J. (2003). CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am. J. Clin. Pathol. 120, 760-766.
pubmed: 14608904
Scott D.W., Abrisqueta P., Wright G.W., Slack G.W., Mottok A., Villa D., Jares P., Rauert-Wunderlich H., Royo C., Clot G., Pinyol M., Boyle M., Chan F.C., Braziel R.M., Chan W.C., Weisenburger D.D., Cook J.R., Greiner T.C., Fu K., Ott G., Delabie J., Smeland E.B., Holte H., Jaffe E.S., Steidl C., Connors J.M., Gascoyne R.D., Rosenwald A., Staudt L.M., Campo E., Rimsza L.M. and Project Lymphoma/Leukemia Molecular Profiling. (2017). New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J. Clin. Oncol. 35, 1668-1677.
pmcid: PMC5455765
pubmed: 28291392
Shanmugam V., Craig J.W., Hornick J.L., Morgan E.A., Pinkus G.S. and Pozdnyakova O. (2017). Cyclin D1 is expressed in neoplastic cells of Langerhans cell histiocytosis but not reactive Langerhans cell proliferations. Am. J. Surg. Pathol. 41, 1390-1396.
pubmed: 28622183
Shrestha R., Bhatt V.R., Guru Murthy G.S. and Armitage J.O. (2015). Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. Leuk. Lymphoma 56, 2759-2767.
pubmed: 25747972
Song J.Y., Song L., Herrera A.F., Venkataraman G., Murata-Collins J.L., Bedell V.H., Chen Y.Y., Kim Y.S., Tadros R., Nathwani B.N., Weisenburger D.D. and Feldman A.L. (2016). Cyclin D1 expression in peripheral T-cell lymphomas. Mod. Pathol. 29, 1306-1312.
pmcid: PMC5576450
pubmed: 27469326
Specht K., Haralambieva E., Bink K., Kremer M., Mandl-Weber S., Koch I., Tomer R., Hofler H., Schuuring E., Kluin P.M., Fend F. and Quintanilla-Martinez L. (2004). Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104, 1120-1126.
pubmed: 15090460
Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D. and Jaffe E.S. (2016a). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375-2390.
pmcid: PMC4874220
pubmed: 26980727
Swerdlow S.H., Kuzu I., Dogan A., Dirnhofer S., Chan J.K., Sander B., Ott G., Xerri L., Quintanilla-Martinez L. and Campo E. (2016b). The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 468, 259-275.
pmcid: PMC5002945
pubmed: 26454445
The Non-Hodgkin's Lymphoma Classification Project. (1997). A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89, 3909-3918.
pubmed: 9166827
Vasef M.A., Medeiros L.J., Koo C., McCourty A. and Brynes R.K. (1997). Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am. J. Clin. Pathol. 108, 302-307.
pubmed: 9291459
Vegliante M.C., Palomero J., Perez-Galan P., Roue G., Castellano G., Navarro A., Clot G., Moros A., Suarez-Cisneros H., Bea S., Hernandez L., Enjuanes A., Jares P., Villamor N., Colomer D., Martin-Subero J.I., Campo E. and Amador V. (2013). SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 121, 2175-2185.
pubmed: 23321250
Visco C., Hoeller S., Malik J.T., Xu-Monette Z.Y., Wiggins M.L., Liu J., Sanger W.G., Liu Z., Chang J., Ranheim E.A., Gradowski J.F., Serrano S., Wang H.Y., Liu Q., Dave S., Olsen B., Gascoyne R.D., Campo E., Swerdlow S.H., Chan W.C., Tzankov A. and Young K.H. (2011). Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am. J. Surg. Pathol. 35, 177-189.
pmcid: PMC3079277
pubmed: 21263238
Vogt N. and Klapper W. (2013). Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology 62, 334-342.
pubmed: 23240716
Wang X., Asplund A.C., Porwit A., Flygare J., Smith C.I., Christensson B. and Sander B. (2008). The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br. J. Haematol. 143, 248-252.
pubmed: 18729857
Wang L., Tang G., Medeiros L.J., Xu J., Huang W., Yin C.C., Wang M., Jain P., Lin P. and Li S. (2020). MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica 106, 1381-1389.
pmcid: PMC8094099
pubmed: 32273477
Xu J., Medeiros L.J., Saksena A., Wang M., Zhou J., Li J., Yin C.C., Tang G., Wang L., Lin P. and Li S. (2018). CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 9, 11441-11450.
pmcid: PMC5837746
pubmed: 29545910
Xu J., Wang L., Li J., Saksena A., Wang S.A., Shen J., Hu Z., Lin P., Tang G., Yin C.C., Wang M., Medeiros L.J. and Li S. (2019). SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Am. J. Surg. Pathol. 43, 710- 716.
pubmed: 30768440
Zeng W., Fu K., Quintanilla-Fend L., Lim M., Ondrejka S. and His E.D. (2012). Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am. J. Surg. Pathol. 36, 214-219.
pubmed: 22251940